Later, we combined CYP1A1, CYP2B6, CYP3A4, UGT1A8, UGT2B11, UGT2B17, UGT2B7, GAS5, XIST, SNHG6, which showed good correlations to chemotherapy or endocrine therapy resistance, to predict drug response and treatment outcomes in 69 PCa patients who have previously received chemotherapy or endocrine therapy. Here, GAS5 is linked to posterior cortical atrophy.